search
Back to results

Obalon Balloon System Pivotal IDE (SMART) Trial (SMART)

Primary Purpose

Obesity

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Obalon Intragastric Balloons
Sham Device
Nutrition and Lifestyle Program
Sponsored by
Obalon Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring Weight Loss, Obesity, BMI

Eligibility Criteria

22 Years - 64 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female between the ages of 22-64 years
  2. Current BMI of 30.0 - 40 kg/m2
  3. Previously attempted to lose weight unsuccessfully using a medically supervised or non-medically supervised diet
  4. Willing to attend all protocol-specified follow-up visits plus any additional follow-up visits as required throughout the entire study period
  5. Willing to avoid non-commercial air travel and scuba diving during the entire study period
  6. Willing to avoid medications or other substances known to effect weight changes during the study
  7. Willing to avoid Non-Steroidal Anti-inflammatory Drugs (NSAIDs) or other medications known to be gastric irritants during the study
  8. Willing to use contraception and avoid pregnancy during the study if the subject is female with child bearing potential
  9. Willing to provide written informed consent

Exclusion Criteria:

  1. Significant weight loss in the past 12 months
  2. Use of medications or other substances known to induce weight gain or weight loss
  3. Participation in any clinical study at the start of this trial or in the last year
  4. Known history of endocrine disorders affecting weight
  5. Currently receiving chronic steroid or immunosuppressive therapy or has previously been diagnosed with HIV
  6. Subjects diagnosed with bulimia, binge eating, compulsive overeating, high liquid calorie intake habits or similar eating related psychological disorders
  7. Intent to undergo gastric surgery or gastric banding during the study period or within the 6 month period after completion of this study
  8. Prior use of any weight loss medical device
  9. Known history of structural or functional disorders of the esophagus
  10. Known history of structural or functional disorder of the esophagus, including any swallowing disorder, esophageal chest pain disorders, or drug refractory esophageal reflux symptoms
  11. Known history of structural or functional disorders of the stomach
  12. Known history of a structural or functional disorder of the stomach, including any symptoms of chronic upper abdominal pain, chronic nausea, chronic vomiting, chronic dyspepsia or symptoms suggestive of gastroparesis, including post-prandial fullness or pain, post-prandial nausea or vomiting or early satiety
  13. Known history of duodenal ulcer, intestinal diverticula (diverticulitis), intestinal varices, intestinal stricture/stenosis, small bowel obstruction, or any other obstructive disorder of the gastrointestinal (GI) tract
  14. Currently have ongoing symptoms suggestive of intermittent small bowel obstruction, such as recurrent bouts of post-prandial abdominal pain, nausea or vomiting
  15. Known history irritable bowel syndrome, radiation enteritis or other inflammatory bowel disease, such as Crohn's disease
  16. Known history of GI surgeries that may have resulted in anatomical GI tract abnormalities
  17. Type 1 diabetes
  18. Type 2 diabetes requiring insulin or other hypoglycemic oral agents.
  19. Experienced a myocardial infarction, has a known history of angina, a known history of congestive heart failure, or is currently being medically treated for any other cardiac condition
  20. Poorly controlled hypertension, (≥ 160 mmHg Systolic and ≥ 100mmHg Diastolic).
  21. End stage renal disease or requiring hemodialysis within the past 6 months
  22. Unwilling or unable to avoid Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including Aspirin, Diclofenac, Ibuprofen, Naproxen, or other medications known to be gastric irritants beginning two weeks prior to enrollment and throughout the entire study period
  23. Subjects taking medications on specified hourly intervals that may be affected by changes to gastric emptying
  24. Subjects requiring the use of anti-platelet drugs or other agents affecting the normal clotting of blood
  25. Untreated or unstable alcohol or illicit drug addiction
  26. Known history of allergies to any component of the device materials
  27. Currently pregnant or breastfeeding or intention of becoming pregnant during the study
  28. Life expectancy less than 1 year or severe renal, hepatic, pulmonary or other medical condition, in the opinion of the investigator
  29. Subject is employed by the investigator, or is a close relative of the investigator, or the investigator's staff
  30. Subject is a close relative of another subject already enrolled in the study.
  31. Any other condition that, in the opinion of the investigator, would interfere with subject participation, may confound the study results, or interfere with compliance with the study (e.g., psychosocial issues).

Sites / Locations

  • HonorHealth Research Institute
  • Anaheim Clinical Trials
  • Southern California Research Center
  • Bariatric Institute of Greater Chicago
  • Endoscopic Microsurgery Associates
  • Saint Luke's Hospital of Kansas City
  • Washington University Hospital in St. Louis
  • Stony Brook Medicine
  • West Penn Hospital
  • Chattanooga Bariatrics
  • Midsouth Bariatrics
  • Vanderbilt University Medical Center
  • Houston Methodist Research Institute
  • University of Utah Hospital
  • Virginia Mason Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

Treatment Group

Control Group

Arm Description

In accordance with the randomization assignment, treatment arm subjects will receive a 6-month course of Balloon therapy with a nutrition and lifestyle program. Balloon treatment consists of placement of 3 balloons Obalon Intragastric Balloons in the first 3 months of therapy.

Control arm subjects will receive a single 6-month course of sham device therapy with a nutrition and lifestyle program. Sham treatment consists of placement of 3 shams in the first 3 months of therapy.

Outcomes

Primary Outcome Measures

Least-Square Mean Difference in % Total Body Loss (TBL) Between the Obalon Treatment and Sham Control Groups
Statistical test to determine if the least-square mean difference between the Obalon Treatment and Sham Control groups is greater than the 2.1% TBL superiority margin
Percentage of Subjects in the Obalon Treatment Group With at Least 5% Total Body Loss (TBL)
Statistical test to determine if the percentage of subjects in the Obalon Treatment and Sham Control with at least 5% Total Body Loss (TBL) is greater than 35%

Secondary Outcome Measures

Full Information

First Posted
September 8, 2014
Last Updated
February 6, 2018
Sponsor
Obalon Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02235870
Brief Title
Obalon Balloon System Pivotal IDE (SMART) Trial
Acronym
SMART
Official Title
The Six-Month Adjunctive Weight Reduction Therapy (SMART) Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
February 2015 (undefined)
Primary Completion Date
November 2015 (Actual)
Study Completion Date
May 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Obalon Therapeutics, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This pivotal trial of the Obalon Balloon System is intended to generate safety and effectiveness data required to support a future marketing application. The trial has been designed to evaluate a 6-month use of the Obalon Balloon System as an adjunct to a nutrition and lifestyle behavior modification program. Weight loss will be evaluated after the 6-month course to determine if a specific predefined superiority margin can be achieved in the device group compared to a sham-control group.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Weight Loss, Obesity, BMI

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
711 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment Group
Arm Type
Active Comparator
Arm Description
In accordance with the randomization assignment, treatment arm subjects will receive a 6-month course of Balloon therapy with a nutrition and lifestyle program. Balloon treatment consists of placement of 3 balloons Obalon Intragastric Balloons in the first 3 months of therapy.
Arm Title
Control Group
Arm Type
Sham Comparator
Arm Description
Control arm subjects will receive a single 6-month course of sham device therapy with a nutrition and lifestyle program. Sham treatment consists of placement of 3 shams in the first 3 months of therapy.
Intervention Type
Device
Intervention Name(s)
Obalon Intragastric Balloons
Intervention Description
Intragastric Balloon System to aid in portion control.
Intervention Type
Device
Intervention Name(s)
Sham Device
Intervention Description
Sham Intragastric Balloon
Intervention Type
Behavioral
Intervention Name(s)
Nutrition and Lifestyle Program
Intervention Description
Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.
Primary Outcome Measure Information:
Title
Least-Square Mean Difference in % Total Body Loss (TBL) Between the Obalon Treatment and Sham Control Groups
Description
Statistical test to determine if the least-square mean difference between the Obalon Treatment and Sham Control groups is greater than the 2.1% TBL superiority margin
Time Frame
24 Weeks
Title
Percentage of Subjects in the Obalon Treatment Group With at Least 5% Total Body Loss (TBL)
Description
Statistical test to determine if the percentage of subjects in the Obalon Treatment and Sham Control with at least 5% Total Body Loss (TBL) is greater than 35%
Time Frame
6 months
Other Pre-specified Outcome Measures:
Title
Percentage of Subjects With at Least 5% Total Body Loss: Obalon - Sham Group
Description
Difference in percentage of subjects between the Obalon Treatment and Sham Control groups with at least 5% Total Body Loss (TBL)
Time Frame
6 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female between the ages of 22-64 years Current BMI of 30.0 - 40 kg/m2 Previously attempted to lose weight unsuccessfully using a medically supervised or non-medically supervised diet Willing to attend all protocol-specified follow-up visits plus any additional follow-up visits as required throughout the entire study period Willing to avoid non-commercial air travel and scuba diving during the entire study period Willing to avoid medications or other substances known to effect weight changes during the study Willing to avoid Non-Steroidal Anti-inflammatory Drugs (NSAIDs) or other medications known to be gastric irritants during the study Willing to use contraception and avoid pregnancy during the study if the subject is female with child bearing potential Willing to provide written informed consent Exclusion Criteria: Significant weight loss in the past 12 months Use of medications or other substances known to induce weight gain or weight loss Participation in any clinical study at the start of this trial or in the last year Known history of endocrine disorders affecting weight Currently receiving chronic steroid or immunosuppressive therapy or has previously been diagnosed with HIV Subjects diagnosed with bulimia, binge eating, compulsive overeating, high liquid calorie intake habits or similar eating related psychological disorders Intent to undergo gastric surgery or gastric banding during the study period or within the 6 month period after completion of this study Prior use of any weight loss medical device Known history of structural or functional disorders of the esophagus Known history of structural or functional disorder of the esophagus, including any swallowing disorder, esophageal chest pain disorders, or drug refractory esophageal reflux symptoms Known history of structural or functional disorders of the stomach Known history of a structural or functional disorder of the stomach, including any symptoms of chronic upper abdominal pain, chronic nausea, chronic vomiting, chronic dyspepsia or symptoms suggestive of gastroparesis, including post-prandial fullness or pain, post-prandial nausea or vomiting or early satiety Known history of duodenal ulcer, intestinal diverticula (diverticulitis), intestinal varices, intestinal stricture/stenosis, small bowel obstruction, or any other obstructive disorder of the gastrointestinal (GI) tract Currently have ongoing symptoms suggestive of intermittent small bowel obstruction, such as recurrent bouts of post-prandial abdominal pain, nausea or vomiting Known history irritable bowel syndrome, radiation enteritis or other inflammatory bowel disease, such as Crohn's disease Known history of GI surgeries that may have resulted in anatomical GI tract abnormalities Type 1 diabetes Type 2 diabetes requiring insulin or other hypoglycemic oral agents. Experienced a myocardial infarction, has a known history of angina, a known history of congestive heart failure, or is currently being medically treated for any other cardiac condition Poorly controlled hypertension, (≥ 160 mmHg Systolic and ≥ 100mmHg Diastolic). End stage renal disease or requiring hemodialysis within the past 6 months Unwilling or unable to avoid Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including Aspirin, Diclofenac, Ibuprofen, Naproxen, or other medications known to be gastric irritants beginning two weeks prior to enrollment and throughout the entire study period Subjects taking medications on specified hourly intervals that may be affected by changes to gastric emptying Subjects requiring the use of anti-platelet drugs or other agents affecting the normal clotting of blood Untreated or unstable alcohol or illicit drug addiction Known history of allergies to any component of the device materials Currently pregnant or breastfeeding or intention of becoming pregnant during the study Life expectancy less than 1 year or severe renal, hepatic, pulmonary or other medical condition, in the opinion of the investigator Subject is employed by the investigator, or is a close relative of the investigator, or the investigator's staff Subject is a close relative of another subject already enrolled in the study. Any other condition that, in the opinion of the investigator, would interfere with subject participation, may confound the study results, or interfere with compliance with the study (e.g., psychosocial issues).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amy VandenBerg
Organizational Affiliation
Obalon Therapeutics, Inc.
Official's Role
Study Chair
Facility Information:
Facility Name
HonorHealth Research Institute
City
Scottsdale
State/Province
Arizona
Country
United States
Facility Name
Anaheim Clinical Trials
City
Anaheim
State/Province
California
Country
United States
Facility Name
Southern California Research Center
City
Coronado
State/Province
California
Country
United States
Facility Name
Bariatric Institute of Greater Chicago
City
Hinsdale
State/Province
Illinois
Country
United States
Facility Name
Endoscopic Microsurgery Associates
City
Towson
State/Province
Maryland
Country
United States
Facility Name
Saint Luke's Hospital of Kansas City
City
Kansas City
State/Province
Missouri
Country
United States
Facility Name
Washington University Hospital in St. Louis
City
Saint Louis
State/Province
Missouri
Country
United States
Facility Name
Stony Brook Medicine
City
Stony Brook
State/Province
New York
Country
United States
Facility Name
West Penn Hospital
City
Pittsburgh
State/Province
Pennsylvania
Country
United States
Facility Name
Chattanooga Bariatrics
City
Chattanooga
State/Province
Tennessee
Country
United States
Facility Name
Midsouth Bariatrics
City
Memphis
State/Province
Tennessee
Country
United States
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
Country
United States
Facility Name
Houston Methodist Research Institute
City
Houston
State/Province
Texas
Country
United States
Facility Name
University of Utah Hospital
City
Salt Lake City
State/Province
Utah
Country
United States
Facility Name
Virginia Mason Medical Center
City
Seattle
State/Province
Washington
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Obalon Balloon System Pivotal IDE (SMART) Trial

We'll reach out to this number within 24 hrs